A phase I/II study of the safety and efficacy of telaglenastat (CB-839) in combination with nivolumab in patients with metastatic melanoma, renal cell carcinoma, and non-small-cell lung cancer

Mohamed A. Gouda, Funda Meric‐Bernstam, Vasudha Katragadda et al.|ESMO Open|2025

Cited by 54